In primary breast cancer (PBC), Kleer et al. [17] showed that EZH2 overexpression was further associated with a larger tumor size, ER- and PR-negative status, an advanced stage of disease, and significantly reduced disease-free survival (DFS) and overall survival (OS). The gene discussed is EZH2; the disease is primary biliary cholangitis.